Similarly, low FST expression is associated with poor prognosis in patients with triple-negative BC (TNBC) [25] and overexpression of FST in a mouse model of HER2/Neu-induced metastatic BC has a huge inhibitory effect on metastases [26]. Here, ERBB2 is linked to breast cancer.